|Targets||Checkpoint Kinase (Chk)|
|Description||NSC-109555 Ditosylate is an ATP-competitive Chk2 inhibitor with IC50 value of 0.2 μM. It acts by inhibiting histone H1 phosphorylation and attenuating mitochondrial ATP synthesis. It is an antileukemic agent.|
|Purity||≥98% by HPLC|
|Synonyms||NSC-109555 Ditosylate; NSC 109555 Ditosylate; NSC109555 Ditosylate; 4,4'-diacetyldiphenylurea bis(guanylhydrazone) ditosylate|
CCT245737 is an orally bioactive CHK1 inhibitor (IC50 of 1.4 nM), displaying >1,000-fold selectivity against CHK2 and CDK1. It potently inhibits cellular CHK1 a...
The dihydrochloride salt form of LY2606368 which also known as prexasertib, is an inhibitor of checkpoint kinase 1 and has potential effect in antineoplastic. I...
LY2603618 is a potent and selective small molecule inhibitor of Chk1 protein kinase activity in vitro (IC50=7 nM) and the first selective Chk1 inhibitor to ente...
Prexasertib, also known as LY2606368, is an ATP-competitive CHK1 inhibitor (Ki= 0.9 nmol/L), with minor activity against CHK2 and RSK with IC50= 8 nM and 9 nM r...
CCT245737, a nitrogen heterocycle compound, has been found to be a CHK1 inhibitor that could probable be effective in antineoplastic studies. It is still under ...
An inhibitor of CHK1 and CHK2
NSC 109555 ditosylate
NSC-109555 Ditosylate is an ATP-competitive Chk2 inhibitor with IC50 value of 0.2 μM. It acts by inhibiting histone H1 phosphorylation and attenuating mitochond...
TCS 2312 is a potent checkpoint kinase 1 (chk1) inhibitor (Ki = 0.38 nM, EC50 = 60 nM). TCS 2312 potentiates the cell killing activity of Gemcitabine in breast ...